| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6036942 | COVIS | Seal configuration for aerosol canister |
Apr, 2013
(10 years ago) | |
| US5605674 | COVIS | Medicinal aerosol formulations |
Feb, 2014
(10 years ago) | |
| US5683677 | COVIS | Medicinal aerosol formulations |
Nov, 2014
(9 years ago) | |
| US5775321 | COVIS | Seal configuration for aerosol canister |
Jul, 2015
(8 years ago) | |
| US6006745 | COVIS | Device for delivering an aerosol |
Dec, 2016
(7 years ago) | |
| US6264923 | COVIS | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(5 years ago) | |
| US6120752 | COVIS | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(5 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(3 years from now) | |
Zetonna is owned by Covis.
Zetonna contains Ciclesonide.
Zetonna has a total of 9 drug patents out of which 8 drug patents have expired.
Expired drug patents of Zetonna are:
- US6036942
- US5605674
- US5683677
- US5775321
- US6006745
- US6264923
- US6120752
- US5482934
Zetonna was authorised for market use on 20 January, 2012.
Zetonna is available in aerosol, metered;nasal dosage forms.
Zetonna can be used as treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child, method of treating inflammatory conditions.
The generics of Zetonna are possible to be released after 01 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 20, 2015 |
Drugs and Companies using CICLESONIDE ingredient
Market Authorisation Date: 20 January, 2012
Treatment: Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child;...
Dosage: AEROSOL, METERED;NASAL
ZETONNA family patents
